These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17921105)

  • 1. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment.
    Grande C; Villanueva MJ; Huidobro G; Casal J
    Clin Transl Oncol; 2007 Sep; 9(9):578-81. PubMed ID: 17921105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature.
    Genestreti G; Di Battista M; Trisolini R; Denicolò F; Valli M; Lazzari-Agli LA; Dalpiaz G; De Biase D; Bartolotti M; Cavallo G; Brandes AA
    Tumori; 2015 Jun; 101(3):e92-5. PubMed ID: 25908033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
    Etienne B; Pérol M; Nesme P; Vuillermoz S; Robinet G; Guérin JC
    Rev Mal Respir; 1998 Apr; 15(2):199-203. PubMed ID: 9608992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.
    Tamiya A; Naito T; Miura S; Morii S; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Yamamoto N; Endo M
    Anticancer Res; 2012 Mar; 32(3):1103-6. PubMed ID: 22399640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
    Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
    Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer.
    Leimgruber K; Negro R; Baier S; Moser B; Resch G; Sansone S; Adami M; Zanon P; Graiff C; Egarter-Vigl E; Wiedermann CJ
    Tumori; 2006; 92(6):542-4. PubMed ID: 17260498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
    Onishi H; Kuriyama K; Yamaguchi M; Komiyama T; Tanaka S; Araki T; Nishikawa K; Ishihara H
    Lung Cancer; 2003 Apr; 40(1):79-84. PubMed ID: 12660011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
    Paz-Ares L; Ross H; O'Brien M; Riviere A; Gatzemeier U; Von Pawel J; Kaukel E; Freitag L; Digel W; Bischoff H; García-Campelo R; Iannotti N; Reiterer P; Bover I; Prendiville J; Eisenfeld AJ; Oldham FB; Bandstra B; Singer JW; Bonomi P
    Br J Cancer; 2008 May; 98(10):1608-13. PubMed ID: 18475293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
    Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
    J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].
    Luiting J; de Monchy JG; Hiltermann TJ; Oude Elberink JN
    Ned Tijdschr Geneeskd; 2011; 155():A2980. PubMed ID: 21527052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment.
    Jin Y; Sun Y; Shi X; Zhao J; Shi L; Hong W; Yu X
    Clin Ther; 2014 Dec; 36(12):1980-1990. PubMed ID: 25256387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-dimensional radiotherapy and docetaxel in treatment of stage III non-small cell lung carcinoma: no good survival due to radiation pneumonitis.
    Dinçbas FO; Atalar B; Koca S
    Lung Cancer; 2004 Feb; 43(2):241-2. PubMed ID: 14739045
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.